Skip to main content

Table 1 Physician-reported reasons for choosing the 2nd line drug

From: Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Variable

Nilotinib

Dasatinib

Totaln (%)

p-value(2 sided)

Accessibility of the drug in physician institution

 Not at all

34 (94.44)

29 (93.55)

63 (94.03)

1

 Very much

2 (5.56)

2 (6.45)

4 (5.97)

 

Cost of drug

 Not at all

33 (91.67)

29 (93.55)

62 (92.54)

0.081

 A little

3 (8.33)

0 (0)

3 (4.48)

 

 Quite a bit

0 (0)

2 (6.45)

2 (2.99)

 

Patient comorbidity profile

 Not at all

15 (41.67)

13 (41.94)

28 (41.79)

0.977

 A little

6 (16.67)

4 (12.9)

10 (14.93)

 

 Quite a bit

13 (36.11)

13 (41.94)

26 (38.81)

 

 Very much

2 (5.56)

1 (3.23)

3 (4.48)

 

Patient’s age

 Not at all

18 (50)

13 (41.94)

31 (46.27)

0.797

 A little

5 (13.89)

7 (22.58)

12 (17.91)

 

 Quite a bit

11 (30.56)

10 (32.26)

21 (31.34)

 

 Very much

2 (5.56)

1 (3.23)

3 (4.48)

 

Patient’s personality profile

 Not at all

9 (25)

11 (35.48)

20 (29.85)

0.534

 A little

7 (19.44)

8 (25.81)

15 (22.39)

 

 Quite a bit

18 (50)

10 (32.26)

28 (41.79)

 

 Very much

2 (5.56)

2 (6.45)

4 (5.97)

 

Previous discussion about Pros and Cons of both treatments

 Not at all

5 (13.89)

3 (9.68)

8 (11.94)

0.455

 A little

3 (8.33)

7 (22.58)

10 (14.93)

 

 Quite a bit

24 (66.67)

18 (58.06)

42 (62.69)

 

 Very much

4 (11.11)

3 (9.68)

7 (10.45)

 

Different treatment schedules

 Not at all

21 (58.33)

13 (41.94)

34 (50.75)

0.615

 A little

6 (16.67)

7 (22.58)

13 (19.4)

 

 Quite a bit

7 (19.44)

8 (25.81)

15 (22.39)

 

 Very much

2 (5.56)

3 (9.68)

5 (7.46)

 

Type of mutation during IM therapy

 Not at all

31 (86.11)

26 (83.87)

57 (85.07)

0.460

 Quite a bit

4 (11.11)

2 (6.45)

6 (8.96)

 

 Very much

1 (2.78)

3 (9.68)

4 (5.97)